Meningitis

Wyeth now able to fulfill E.U. needs for Prevenar

Published in Vaccine Weekly, September 22nd, 2004

The marketing authorization holder for Prevenar, Wyeth Lederle Vaccines, has informed the European Medicines Agency (EMEA) that they are now able to deliver enough doses of the vaccine to the E.U. Member States in which it is marketed.

This follows an earlier statement by the EMEA on March 22, 2004, concerning supply shortages.

While delivery capacity is being resumed, the EMEA and its committee for medicinal products for human use (CHMP) recommend that the appropriate national authorities implement the following revised proposals on the use of Prevenar:

High-risk children (those with medical conditions such as splenic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-09-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry